Budget Impact Analysis of Step-Down Strategy Versus Conventional Therapy in the Treatment of Nosocomial Pneumonia Caused by Gram Positive Bacteria in Mexico

Abstract

The aim of the study was to estimate the budget impact of SDS vs conventional strategy (CS, only intravenous) with linezolid in Mexico, from the perspective of Instituto Mexicano del Seguro Social (IMSS). Methods: Budget impact analysis (BIA) considered direct medical costs of linezolid (intravenous and tablets), length of stay, physician visits, route of administration, laboratory and imaging tests, as well as outpatient control (unit costs extracted from IMSS sources). Costs are expressed in 2013 US$ (1US$:€ 0.719). The resource use profile was estimated by Delphi method in a panel of 10 experienced infectologists. A BIA considering two scenarios was performed: i) budget impact of use CS in 100% of cases of nosocomial pneumonia caused by GPB (15,135) and ii) budget impact of use of SDS only in candidates (7,718 cases), based on the National budget allocated to health in 2013. Results: The per-patient average treatment cost (ATC)